Paul stepping down as Karuna CSO
Plus: leadership changes at Valo and more from Mirum, Arvinas, Vaxcyte, Lantern and Inhibikase
Karuna Therapeutics Inc. (NASDAQ:KRTX) announced in an SEC filing the resignation of Steve Paul as CSO and president of R&D, while remaining a board member. He’ll join the company’s SAB, and founder and COO Andrew Miller will become president of R&D. Karuna also named VP of Legal Affairs Mia Kelley as general counsel. Bristol Myers Squibb Co. (NYSE:BMY) is acquiring Karuna for $14 billion in December.
Flagship Pioneering portfolio company Valo Health Inc. appointed Christian Schade as executive chairman and named Graeme Bell interim CEO. Bell succeeds David Berry, a Flagship general partner who has been CEO since the biotech launched in 2019. Schade, a Flagship growth partner, joined Valo’s board in September. Bell has been EVP and CFO since 2020 and has had multiple operational duties, including chief people officer. Valo’s cloud computing platform is geared to guide everything from target discovery to clinical trial design...